Programmed death ligand 1 (PD-L1) positivity, T cell-inflamed phenotype, and high tumor mutational burden have been reported to enrich the patient populations that benefit from the treatment of immune checkpoint inhibitors (ICIs) [11,12,13,14,15]; however, these makers alone are insufficiently accurate for patient selection across different cancer types. This evidence concerns the gene CD274 and neoplasm.